Navigation Links
First positive results toward a therapeutic vaccine against brain cancer

Astrocytomas and oligodendrogliomas are subtypes of a brain cancer called 'glioma'. These incurable brain tumors arise from glial cells, a type of support cell found in the central nervous system. "Low-grade gliomas", which grow comparatively slowly, spread in a diffuse manner across the brain and are very difficult to completely eliminate through surgery. In many cases, the effectiveness of treatments with chemotherapy and radiotherapy is very limited. Gliomas can develop into extremely aggressive glioblastomas.

Low-grade gliomas have a particular feature in common: more than 70% of the cases exhibit the same gene mutation in tumor cells. An identical "typo" in the DNA causes the exchange of a single, specific protein building block (amino acid) in an enzyme called isocitrate dehydrogenase 1 (IDH1). As a result, most cancer cells do not follow the original building plan for the protein; at the 132nd position in the molecule's sequence, they insert the amino acid histidine instead of arginine.

"This frequent and highly specific mutation immediately aroused our attention as immunologists: In the cancer cells, the exchange of amino acids lends the protein novel properties that can be recognized by the body's own immune cells," says Prof. Dr. Michael Platten, who heads the Clinical Cooperation Unit "Neuroimmunology and Brain Tumor Immunology" at the DKFZ; he also works as a senior consultant in the Department of Neurooncology of Heidelberg University Hospital.

No other type of tumor displays the same mutation with such frequency. The mutant protein can reliably be detected using a highly specific antibody developed by Prof. Dr. Andreas von Deimling, a neuropathologist at the University Hospital and the DKFZ. This form of IDH1 is present on the surface of all tumor cells and is completely specific to the tumor. "This suggested that we might be able to use a vaccine to alert the patient's immune system to mutant IDH1, fighting the tumor without damaging healthy cells," Platten explains.

In collaboration with a team of physicians and scientists from Heidelberg University Hospital, DKFZ and the Universities of Mainz, Tbingen and Hamburg, Platten and his co-workers have now made the first successful step toward a vaccine that specifically targets the mutation in the tumor.

The researchers constructed an artificial version of the segment of IDH1 with the characteristic mutation using individual amino acids. This version of the peptide, which consisted of 15 building blocks, exactly matched one of the presentation molecules on the surface of the tumor cells. This is essential, because immune cells only respond to a target that is presented on so-called "MHC molecules" on the cell surface. If there is no such matching presentation, the body will not amount an immune response.

To draw conclusions about the human immune system from the vaccination experiments, the researchers used mice whose cells were equipped with human MHC molecules. "After vaccinating the animals with the peptide, we were able to detect immune cells and antibodies that specifically recognized the altered IDH1 of tumor cells rather than the normal form of the enzyme in healthy cells," says Dr. Theresa Schumacher, first author of the study.

In the experimental animals, this specific immune response induced by the vaccination arrested the growth of cancer cells that exhibited the characteristic IDH1 mutation. As hoped, the vaccination did not disrupt the functioning of the normal IDH1 enzyme, which plays a role in the energy metabolism of all healthy cells in the body.

"In some patients with low-grade glioma we also found spontaneous immune responses against altered IDH1," Platten says. "This is a good sign; it suggests that vaccinations based on the peptide can in fact support the body's own immune system in fighting cancer cells." This gives a "vaccination therapy" good chances of success, according to the Heidelberg physicians. In a clinical trial scheduled to start early next year, with the support of the German Consortium for Translational Cancer Research (DKTK), they plan to examine the safety of the vaccine against gliomas based on mutant IDH1 in human patients, for the first time.

"Most low-grade gliomas cannot be removed completely by surgery and thus often recur," says Prof. Wolfgang Wick, Medical Director of the Department of Neurooncology and head of the Clinical Cooperation Unit "Neurooncology" at the DKFZ. "Patients would therefore benefit tremendously from a vaccine that prevents this from happening."


Contact: Dr. Sibylle Kohlstädt
German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)

Related biology news :

1. Drug shows promise for the first time against metastatic melanoma of the eye
2. Super bananas -- world first human trial
3. Findings point toward one of first therapies for Lou Gehrigs disease
4. Alcohol abuse damage in neurones at a molecular scale identified for first time
5. Spectrum Health among first to implant neurostimulator for epilepsy
6. Public gets first view of a live vampire squid and other deep-sea cephalopods
7. Reptile Atlas a first for southern Africa
8. First demonstration in human cells of chromosomal translocations that cause certain cancer
9. Tumor chromosomal translocations reproduced for the first time in human cells
10. For the first time in the lab, researchers see stem cells take key step toward development
11. Australias deadly eruptions the reason for the first mass extinction
Post Your Comments:
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... and MAGDEBURG, Germany , November 30, 2015 ... in Vienna, Austria to be ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") ... its Internet-delivered NovaVision Therapy Suite at the 3rd European ...
(Date:11/28/2015)... ... November 28, 2015 , ... • Jeon Jin Bio Corp, ... and rodent control solutions , Bird Free, ... works across all sensory modalities including visual, smell, taste and touch, enabling safe, effective ...
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... la première fois les différences entre les souches ... de celles des êtres humains . Ces ... comprendre et envisager la prise en charge efficace de ... ent diagnostiqués chez les chats .    --> ...
Breaking Biology Technology: